Integrating Biology for Safe Intensification of Glioblastoma Hypofractionated Treatment on the MR-Linac
NCT07457307
Site status not listed — check the official record
- Conditions
- High-grade Glioma
- Interventions
- MR-Linac System, Radiation Therapy, Temozolomide
- Device · Radiation · Drug
- Lead sponsor
- NYU Langone Health
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- New York, New York